Effect of tacrolimus (FK506) on ischemia-induced brain damage and memory dysfunction in rats

Pharmacology Biochemistry and Behavior

Volumn 77, Issue 3, 2004, Pages 607-615

  Benetoli, Arcélio ^a   Paganelli, Ricardo Alexandre ^a   Giordani, Fabíola ^a   Lima, Keli Carina Miltus ^a   Fávero Filho, Luiz António ^a   Milani, Humberto ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

Cerebral ischemia; FK506; Learning and memory; Neurodegeneration; Neuroprotection; Radial maze

Indexed keywords

NEUROPROTECTIVE AGENT; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CELL LOSS; COGNITION; CONTROLLED STUDY; DRUG EFFECT; HIPPOCAMPUS; LEARNING; LONG TERM MEMORY; MALE; MAZE TEST; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; RETROGRADE AMNESIA; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; BRAIN ISCHEMIA; HYPOXIA, BRAIN; MALE; MEMORY DISORDERS; PYRAMIDAL CELLS; RATS; RATS, WISTAR; TACROLIMUS;

EID: 1542300275     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.12.022     Document Type: Article

References (48)

1. Arii T., Kamiya T., Arii K., Ueda M., Nito C., Katsura K.I.et al. Neuroprotective effects of immunosuppressant Fk506 in transient focal ischemia in rat: therapeutic time window for FK506 in transient focal ischemia. Neurol. Res. 23:2001;755-760.
2. Aronowski J., Samways E., Strong R., Rhoades H.M., Grotta J.C. An alternative method for the quantitation of neuronal damage after experimental middle cerebral artery occlusion in rats: analysis of behavioral deficits. J. Cereb. Blood Flow Metab. 16:1996;705-713.
3. Bachevalier J., Meunier M. Cerebral ischemia: are the memory deficits associated with hippocampal cell loss? Hippocampus. 66:1999;553-560.
4. Barnes C.A. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 93(1):1979;74-104.
5. Barnes C.A. Spatial learning and memory processes: the search for their neurobiological mechanisms in the rat. Trends Neurosci. 11(4):1988;163-169.
6. Butcher S.P., Henshal D.C., Teramura Y., Iwasaki K., Sharkey J. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J. Neurosci. 15(18):1997;6939-6946.
7. Colbourne F., Corbett D. Delayed postischemic hypothermia: a six month survival study using behavioral and histological assessments of neuroprotection. J. Neurosci. 15(11):1995;7250-7260.
8. Corbett D., Nurse S. The problem of assessing effective neuroprotective in experimental cerebral ischemia. Prog. Neurobiol. 54:1998;531-548.
9. Cummings J.L., Tomiyasu U., Read S., Benson D.F. Amnesia with hippocampal lesions after cardiopulmonary arrest. Neurology. 34:1984;679-681.
10. Davis H.P., Tribuna J., Pulsinelli W.A., Volpde B.T. Reference and working memory of rats following hippocampal damage induced by transient forebrain ischemia. Physiol. Behav. 37(3):1986;387-392.
11. Davis H.P., Baronowski J.R., Pulsinelli W.A., Volpe B.T. Retention of reference memory following ischemic hippocampal damage. Physiol. Behav. 39:1987;783-786.
12. Dawson T.M., Steiner J.P., Dawson V.L., Dinerman J.L., Uhl G.R., Snyder S.H. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 90:1993;9808-9812.
13. Drake M., Friberg H., Boris-Moller F., Sakata K., Wieloch T. The immunosuppressant FK506 ameliorates ischaemic damage in the rat brain. Acta. Physiol. Scand. 158:1996;155-159.
14. Funahashi S., Kubota K. Working memory and prefrontal cortex. Neurosci. Res. 21(1):1994;1-11.
15. Furuichi Y., Katsuta K., Maeda M., Ueyama N., Moriguchi A., Matsuoka N. et al. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res. 965:2003;137-145.
16. Gionet T.X., Thomas J.D., Warner D.S., Goodlett C.R., Wasserman E.A., West J.R. Forebrain ischemia induces selective behavioral impairments associated with hippocampal injury in rats. Stroke. 22:1991;1040-1047.
17. Giordani F., Benetoli A., Favero-Filho L.A., Lima K.C.M., Cestari J.L., Milani H. Tacrolimus (FK506) reduces ischemia-induced hippocampal damage in rats: a 7- and 30-day study. Braz. J. Med. Biol. Res. 36(4):2003;495-502.
18. Gladstone D.J., Black S.E., Hakim A.M. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 33:2002;2123-2136.
19. Green E.J., Dietrich W.D., Van Dijk F., Busto R., Markgraf C.G., McCabe P.M.et al. Protective effects of brain hypothermia on behavior and histopathology following global cerebral ischemia in rats. Brain Res. 580:1992;197-204.
20. Grotta J.C., Picone C.M., Ostrow P.T., Strong R.A., Earls R.M., Yao L.P.et al. CGS-19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann. Neurol. 27(6):1990;612-619.
21. Hodges H. Maze procedures: the radial-arm and water maze compared. Cogn. Brain Res. 3:1996;167-181.
22. Hunter A.J., Mackay K.B., Rogers D.C. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? Trends Pharmacol. Sci. 19:1998;59-66.
23. Ide T., Morikawa E., Kirino T. An immunosuppressant, FK506, protects hippocampal neurons from forebrain ischemia in the Mongolian gerbil. Neurosci. Lett. 204:1996;157-160.
24. Ishimaru H., Takahashi A., Ikarashi Y., Muruyama Y. Pentobarbital protects against CA1 pyramidal cell death but not dysfunction of hippocampal cholinergic neurons following transient ischemia. Brain Res. 673:1995;112-118.
25. Kiyota Y., Miyamoto M., Nagaoka A. Relationship between brain damage and memory impairment in rats exposed to transient forebrain ischemia. Brain Res. 538:1991;295-302.
26. Klettner A., Baumgrass R., Zhang Y., Fischer G., Burger E., Herdegen T. et al. The neuroprotective actions of FK506 binding protein ligands: neuronal survival is triggered by de novo RNA synthesis, but is independent of inhibition of JNK and calcineurin. Mol. Brain. Res. 97:2001;21-31.
27. Milani H., Yoshie U.M., Rubia M.W.O., Lepri E.R., Xavier G.F. Loss of CA1 cells following global ischaemia correlates with spatial deficits in the circular platform task. J. Neurosci. Methods. 80:1998;19-27.
28. Morioka M., Fukunaga K., Kai Y., Todaka T., Yano S., Hamada J.-I.et al. Intravenously injected FK506 failed to inhibit hippocampal calcineurin. Biochem. Biophys. Res. Commun. 286:2001;802-806.
29. Nunn J., Hodges H. Cognitive deficits induced by global cerebral ischaemia: relationship to brain damage and reversal by transplants. Behav. Brain. Res. 65:1994;1-31.
30. Olton D.S., Markowska A.L. Memory and hippocampal function as targets for neurotoxic substances. Neurol. Toxicol. 15(3):1994;439-444.
31. Paganelli R.A., Benetolli A., Lima K.C.M., Cestari Junior L.A., Favero-Filho L.A., Milani H. A novel version of the 8-arm radial maze: effects of cerebral ischemia on learning and memory. J. Neurosci. Methods. 132:2004;9-18.
32. Petito C.K., Feldmann E., Pulsinelli W.A., Plum F. Delayed hippocampal damage in humans following cardiorespiratory arrest. Neurology. 37:1987;1281-1286.
33. Pulsinelli W.A., Brierley J.B. A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke. 10(3):1979;267-272.
34. Rod M.R., Whishaw I.Q., Aauer R.N. The relationship of structural ischemic brain damage to neurobehavioral deficit: the effect of postischemic MK-801. Can. J. Psychol. 44(2):1990;196-209.
35. Sauer H., Francis J.M., Jiang H., Hamilton G.S., Steiner J.P. Systemic treatment with GPI 1046 improves spatial memory and reverses cholinergic neuron atrophy in the medial septal nucleus of aged mice. Brain Res. 842(1):1999;109-118.
36. Sharkey J., Butcher S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature. 371:1994;336-339.
37. Sharkey J., Crawford J.H., Butcher S.P., Marston H.M. Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. Stroke. 27:1996;2282-2286.
38. Sinson G., Voddi M., McIntosh T.K. Nerve grow factor administration attenuates cognitive but not neurobehavioral motor dysfunction or hippocampal cell loss following fluid-percussion brain injury in rats. J. Neurochem. 65:1995;2209-2216.
39. Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 30:1999;2752-2758.
40. Sudo Y., Takahara Y., Nakajima N. Pulsatile cardiopulmonary bypass failed to prevent neuropsychological dysfunction. Ann. Thorac. Cardiovasc. Surg. 7(2):2001;89-93.
41. Tanaka K.-I., Hori K., Tanaka N.W., Nomura M., Ogawa N. Fk506 ameliorates the discrimination learning impairment due to preventing the rarefaction of white matter induced by chronic cerebral hypoperfusion in rats. Brain Res. 906:2001;184-189.
42. Tokime T., Nozaki K., Kikuchi H. Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil. Neurosci. Lett. 206:1996;81-84.
43. Volpe B.T., Hirst W. The characterization of an amnesic syndrome following hypoxic ischemic injury. Arch. Neurol. 40:1983;436-440.
44. Wakita H., Tomimoto H., Akiguchi I., Kimura J. Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia. Brain Res. 792:1998;105-113.
45. Whishaw I.Q., Rod M.R., Auer R.N. Behavioral deficits revealed by multiple tests in rats with ischemic damage limited to half of the CA1 sector of the hippocampus. Brain. Res. Bull. 34(3):1994;283-289.
46. Yagita Y., Kitagawa K., Matsushita K., Taguchi A., Mabuchi T., Ohtsuki T.et al. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. Life Sci. 59(19):1996;1643-1650.
47. Yoshimoto T., Siesjo B.K. Posttreatment with the immunossuppressant cyclosporin A in transient focal ischemia. Brain Res. 839:1999;283-291.
48. Zola-Morgan S., Squire L.R., Amaral D.G. Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the Hippocampus. J. Neurosci. 6:1986;2950-2967.